# A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France

> **NCT03757013** · — · COMPLETED · sponsor: **Amgen** · enrollment: 453 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT03757013
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-25
- **Primary completion:** 2021-07-21
- **Final completion:** 2021-09-10
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2021-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03757013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03757013, "A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03757013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*